Berberine Can Reduce Inflammation

Berberine and inflammation: Berberine has well-documented anti-inflammatory activity. Mechanistic studies show that it can down-regulate NF-κB signaling and reduce key pro-inflammatory cytokines such as TNF-α and IL-6 [1]. From a cardiovascular perspective, this may be more important than its effects on cholesterol alone. Chronic vascular inflammation—reflected by markers such as C-reactive protein (CRP)—is a strong and independent predictor of cardiovascular events. Despite this, inflammation often receives less attention in routine care than traditional lipid markers.

Studies Support Berberine’s Use

A dose–response meta-analysis of 18 randomized controlled trials involving 1,600 adults found that berberine or barberry supplementation was associated with significant reductions in IL-6, TNF-α, and CRP. Nonlinear analyses suggested that these anti-inflammatory effects were most evident at doses under 1,000 mg/day and with interventions lasting less than five weeks [2]. Multiple other systematic reviews support berberine’s ability to lower CRP and related inflammatory markers across cardiometabolic populations [3,5]. Consistent with this broader anti-inflammatory profile, berberine has also been studied as an adjunct in acute ischemic stroke, where reductions in inflammatory burden appear to translate into clinically meaningful benefits [4].

Despite the strength of CRP as a cardiovascular risk marker, it is often treated as secondary—or ignored altogether—because there are no widely used, patentable therapies designed specifically to lower it. In contrast, cholesterol reduction remains a primary target, not because it is always the dominant driver of risk, but because it is pharmacologically addressable within the current healthcare model. This mismatch between risk biology and therapeutic incentives helps explain why inflammation-driven interventions, including nutraceuticals such as berberine, remain underutilized despite a growing evidence base.